Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma  

作　　者：Yi Wang Yuting Yan Dandan Shan Jiawen Chen Wei Liu Tingyu Wang Gang An WeiweiSui Wenyang Huang Wenjie Xiong Huimin Liu Qi Sun Huijun Wang Zhijian Xiao JianxiangWang Lugui Qiu Dehui Zou Shuhua Yi 

机构地区：[1]State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China [2]Tianjin Institutes of Health Science,Tianjin 301600,China

出　　处：《Cancer Biology & Medicine》2025年第2期177-189,共13页癌症生物学与医学(英文版)

基　　金：supported by grants from the National Natural Science Foundation of China(Grant Nos.82200215,82170193,and 82370197);the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(Grant No.2022-I2M-1-002)。

摘　　要：Objective:Our previous studies have indicated potentially higher proliferative activity of tumor cells in Chinese patients with mantle-cell lymphoma(MCL)than those in Western.Given the success and tolerability of R-DA-EDOCH immunochemotherapy in treating aggressive B-cell lymphomas,we designed a prospective,phase 3 trial to explore the efficacy and safety of alternating R-DA-EDOCH/R-DHAP induction therapy for young patients with newly diagnosed MCL.The primary endpoint was the complete remission rate(CRR)at the end of induction(EOI).Methods:A total of 55 patients were enrolled.The CRR at the EOI was 89.1%[95%confidence interval(CI)78%±96%],and the overall response rate was 98.1%(95%CI 90%±100%).Most patients with bone marrow involvement quickly attained minimal residual disease(MRD)negative status,with a 95.7%rate at the EOI.Results:The 3-year progression-free survival(PFS)and overall survival rates were 66.3%and 83.2%,respectively.No patients discontinued treatment because of adverse events.Univariate analysis identified pathologic morphology and TP53 mutations as risk factors for PFS.However,high tumor proliferative activity and certain cytogenetic abnormalities showed no significant adverse prognostic significance.Conclusions:Intensive therapy based on a high cytarabine dose and continuously administered EDOCH achieved a high MRDnegative rate and provides an optional induction choice for young patients with MCL with high-risk factors.

关 键 词：Mantle cell lymphoma IMMUNOCHEMOTHERAPY high-risk factors minimal residual disease adverse events 

分 类 号：R733.1[医药卫生—肿瘤]